<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <link href="/kxreader/Content/css/detail?v=NOOK-mvTMnxl11s6oPYV0boPXN3iP4N7Rc-A56nk4KI1" rel="stylesheet"/>

    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>
</head>

<body>
    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141669168545000%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dXXGK201903028%26RESULT%3d1%26SIGN%3dDwfYIKyeMEycRs%252fwVjQR8wiV8W4%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201903028&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201903028&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>

    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201903028&amp;v=MjU3MjFyQ1VSN3FmWnVabUZ5amdVTDdKUFRYTVpiRzRIOWpNckk5SGJJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0Y=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#51" data-title="&lt;b&gt;1 流行病学&lt;/b&gt; "><b>1 流行病学</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#53" data-title="&lt;b&gt;2 发病机制&lt;/b&gt; "><b>2 发病机制</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#55" data-title="&lt;b&gt;3 临床表现&lt;/b&gt; "><b>3 临床表现</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#57" data-title="&lt;b&gt;4 诊 断&lt;/b&gt; "><b>4 诊 断</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#59" data-title="&lt;b&gt;5 治 疗&lt;/b&gt; "><b>5 治 疗</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#61" data-title="5.1 一般治疗">5.1 一般治疗</a></li>
                                                <li><a href="#69" data-title="5.2 针对 CTD 的治疗">5.2 针对 CTD 的治疗</a></li>
                                                <li><a href="#71" data-title="5.3 PAH 靶向药物治疗">5.3 PAH 靶向药物治疗</a></li>
                                                <li><a href="#83" data-title="5.4 其他治疗">5.4 其他治疗</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#88" data-title="&lt;b&gt;6 小 结&lt;/b&gt; "><b>6 小 结</b></a><i></i></p>
                                                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="3">


                                    <a id="bibliography_1" title="Cavagna L, Codullo V, Ghio S, et al.Undiagnosed connective tissue diseases:High prevalence in pulmonary arterial hypertension patients[J].Medicinel (Baltimore) , 2016, 95 (39) :e4827." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK88E6CF190AE56E397A298D9FCFB25E9E&amp;v=MTcxODlMVTA1dEJoeEwyOHdhaz1OaWZjWmJ1d2E5ZS8yWTVNWkpwNkNYcE16QjhVbXoxMFFBdnIybUZEQzdDUk1MUHFDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCcg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[1]</b>
                                        Cavagna L, Codullo V, Ghio S, et al.Undiagnosed connective tissue diseases:High prevalence in pulmonary arterial hypertension patients[J].Medicinel (Baltimore) , 2016, 95 (39) :e4827.
                                    </a>
                                </li>
                                <li id="5">


                                    <a id="bibliography_2" title="Simonneau G, Gatzoulis MA, Adatia I, et al.Updated clinical classification of pulmonary hypertension[J].J Am Coll of Cardiol, 2013, 62 (25 Suppl) :D34-41." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14010600322695&amp;v=MTk5NzZGaW5sVXJmSUlGc1hheE09TmlmT2ZiSzhIdERNcVk5Rlora05DblU4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[2]</b>
                                        Simonneau G, Gatzoulis MA, Adatia I, et al.Updated clinical classification of pulmonary hypertension[J].J Am Coll of Cardiol, 2013, 62 (25 Suppl) :D34-41.
                                    </a>
                                </li>
                                <li id="7">


                                    <a id="bibliography_3" >
                                        <b>[3]</b>
                                    Humbert M, Coghlan JG, Ghofrani HA, et al.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease:Results:from PATENT-1 and PATENT-2[J].Ann Rheum Dis, 2017, 76 (2) :422-426.</a>
                                </li>
                                <li id="9">


                                    <a id="bibliography_4" title="Lynch JP, Belperio JA, Saggar R, et al.Pulmonary hypertension complicating connective tissue disease[J].Semin Respir Crit Care Med, 2013, 34 (5) :581-599." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJGT&amp;filename=SJGT13101400003310&amp;v=MzEzMjllWnRGaW5sVXJmSUlGc1hheE09TmlmTWVySzdIOUhOcTQ5RlpPc01EMzA1b0JNVDZUNFBRSC9pclJkR2VycVFUTW53Wg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                        Lynch JP, Belperio JA, Saggar R, et al.Pulmonary hypertension complicating connective tissue disease[J].Semin Respir Crit Care Med, 2013, 34 (5) :581-599.
                                    </a>
                                </li>
                                <li id="11">


                                    <a id="bibliography_5" title="张卓莉.系统性红斑狼疮相关肺动脉高压[J].中国实用内科杂志, 2015, 35 (10) :807-809, 813." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SYNK201510001&amp;v=MDIzNjg2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpnVUw3Sk5qVEZaYkc0SDlUTnI0OUZaWVFLREg4NHZSNFQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[5]</b>
                                        张卓莉.系统性红斑狼疮相关肺动脉高压[J].中国实用内科杂志, 2015, 35 (10) :807-809, 813.
                                    </a>
                                </li>
                                <li id="13">


                                    <a id="bibliography_6" title="Hoeper MM, Bogaard HJ, Condliffe R, et al.Definitions and diagnosis of pulmonary hypertension[J].J Am Coll Cardiol, 2013, 62 (25 Suppl) :D42-D50." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Definitions and diagnosis of pulmonary hypertension">
                                        <b>[6]</b>
                                        Hoeper MM, Bogaard HJ, Condliffe R, et al.Definitions and diagnosis of pulmonary hypertension[J].J Am Coll Cardiol, 2013, 62 (25 Suppl) :D42-D50.
                                    </a>
                                </li>
                                <li id="15">


                                    <a id="bibliography_7" title="Yoshifuji H.Management of borderline pulmonary arterial hypertension associated with connective tissue diseases[J].Nihon Rinsho Meneki Gakkai kaishi, 2014, 37 (6) :454-461." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Management of borderline pulmonary arterial hypertension associated with connective tissue diseases">
                                        <b>[7]</b>
                                        Yoshifuji H.Management of borderline pulmonary arterial hypertension associated with connective tissue diseases[J].Nihon Rinsho Meneki Gakkai kaishi, 2014, 37 (6) :454-461.
                                    </a>
                                </li>
                                <li id="17">


                                    <a id="bibliography_8" title="Hao YJ, Jiang X, Zhou W, et al.Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J].Eur Respir J, 2014, 44 (4) :963-972." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients">
                                        <b>[8]</b>
                                        Hao YJ, Jiang X, Zhou W, et al.Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J].Eur Respir J, 2014, 44 (4) :963-972.
                                    </a>
                                </li>
                                <li id="19">


                                    <a id="bibliography_9" title="Li J, Leng X, Li Z, et al.Chinese SLE treatment and research group registry:III.association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus[J].J Immunology Res, 2014, 2014:809389." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJHD&amp;filename=SJHD14051200000329&amp;v=Mjg2OTJheE09TmlmRGFySzhIdFROclk5RlpPc1BEMzR3b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZzWA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[9]</b>
                                        Li J, Leng X, Li Z, et al.Chinese SLE treatment and research group registry:III.association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus[J].J Immunology Res, 2014, 2014:809389.
                                    </a>
                                </li>
                                <li id="21">


                                    <a id="bibliography_10" title="Boueiz A.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension:Pulmonary arterial hypertension associated with connective tissue diseases[J].Ann Thoracic Med, 2014, 9 (Suppl 1) :S26-S37." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK14061700000035&amp;v=MjE0MjViSzhIdGZOcUk5RlpPc1BESDg4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZzWGF4TT1OaWZjWg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[10]</b>
                                        Boueiz A.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension:Pulmonary arterial hypertension associated with connective tissue diseases[J].Ann Thoracic Med, 2014, 9 (Suppl 1) :S26-S37.
                                    </a>
                                </li>
                                <li id="23">


                                    <a id="bibliography_11" title="荆志成.2010 年中国肺高血压诊治指南[J/OL].中国医学前沿杂志:电子版, 2011, 3 (2) :62-81." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=YXQY201102028&amp;v=MTA1NTVnVUw3SlBEWGFkN0c0SDlETXJZOUhiSVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWo=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[11]</b>
                                        荆志成.2010 年中国肺高血压诊治指南[J/OL].中国医学前沿杂志:电子版, 2011, 3 (2) :62-81.
                                    </a>
                                </li>
                                <li id="25">


                                    <a id="bibliography_12" title="Ruano CA, Lucas RN, Leal CI, et al.Thoracic manifestations of connective tissue diseases[J].Curr Probl Diagn Radiol, 2015, 44 (1) :47-59." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES15122600406507&amp;v=MDM0MzQvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGc1hheE09TmlmT2ZiSzlIOVBPcVk5RllPc0pDWHcrb0JNVDZUNFBRSA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[12]</b>
                                        Ruano CA, Lucas RN, Leal CI, et al.Thoracic manifestations of connective tissue diseases[J].Curr Probl Diagn Radiol, 2015, 44 (1) :47-59.
                                    </a>
                                </li>
                                <li id="27">


                                    <a id="bibliography_13" title="Huang C, Zhang S, Tian Z, et al.Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus?A successful case of SLE-PAH cured by methylprednisolone pulse therapy[J].Lupus, 2014, 23 (14) :1533-1536." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus?A successful case of SLE-PAH cured by methylprednisolone pulse therapy">
                                        <b>[13]</b>
                                        Huang C, Zhang S, Tian Z, et al.Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus?A successful case of SLE-PAH cured by methylprednisolone pulse therapy[J].Lupus, 2014, 23 (14) :1533-1536.
                                    </a>
                                </li>
                                <li id="29">


                                    <a id="bibliography_14" title="Szturmowicz M, Kacprzak A, Ku&lt;mathml id=&quot;31&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mover&gt;&lt;mstyle mathsize=&quot;140%&quot; displaystyle=&quot;true&quot;&gt;&lt;mtext&gt;s&lt;/mtext&gt;&lt;/mstyle&gt;&lt;mo&gt;&#39;&lt;/mo&gt;&lt;/mover&gt;&lt;mspace width=&quot;0.25em&quot; /&gt;&lt;mtext&gt;J&lt;/mtext&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;.Pulmonary hypertension in diffuse parenchymal lung diseases-is there any benefit of PAH-specific therapy?[J].Adv Respir Med, 2017, 85 (4) :216-223." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Pulmonary hypertension in diffuse parenchymal lung diseases-is there any benefit of PAH-specific therapy">
                                        <b>[14]</b>
                                        Szturmowicz M, Kacprzak A, Ku&lt;mathml id=&quot;31&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mover&gt;&lt;mstyle mathsize=&quot;140%&quot; displaystyle=&quot;true&quot;&gt;&lt;mtext&gt;s&lt;/mtext&gt;&lt;/mstyle&gt;&lt;mo&gt;&#39;&lt;/mo&gt;&lt;/mover&gt;&lt;mspace width=&quot;0.25em&quot; /&gt;&lt;mtext&gt;J&lt;/mtext&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;.Pulmonary hypertension in diffuse parenchymal lung diseases-is there any benefit of PAH-specific therapy?[J].Adv Respir Med, 2017, 85 (4) :216-223.
                                    </a>
                                </li>
                                <li id="32">


                                    <a id="bibliography_15" title="Sitbon O, Bertoletti L.Connective tissue disease associated with pulmonary arterial hypertension:management of a patient with severe haemodynamic impairment[J].Eur Respir Rev, 2014, 23 (134) :505-509." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Connective tissue disease associated with pulmonary arterial hypertension:management of a patient with severe haemodynamic impairment">
                                        <b>[15]</b>
                                        Sitbon O, Bertoletti L.Connective tissue disease associated with pulmonary arterial hypertension:management of a patient with severe haemodynamic impairment[J].Eur Respir Rev, 2014, 23 (134) :505-509.
                                    </a>
                                </li>
                                <li id="34">


                                    <a id="bibliography_16" title="Condliffe R, Howard LS.Connective tissue disease-associated pulmonary arterial hypertension[J].F1000Prime Rep, 2015, 7:6." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Connective tissue disease-associated pulmonary arterial hypertension">
                                        <b>[16]</b>
                                        Condliffe R, Howard LS.Connective tissue disease-associated pulmonary arterial hypertension[J].F1000Prime Rep, 2015, 7:6.
                                    </a>
                                </li>
                                <li id="36">


                                    <a id="bibliography_17" title="Sung YK, Chung L.Connective tissue disease-associated pulmonary arterial hypertension[J].Rheum Dis Clin North Am, 2015, 41 (2) :295-313." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJESC5BEEC0C15A31024372267BA80106542&amp;v=MTY1NDl0Qmh4TDI4d2FrPU5pZk9mY0M5YktTNTNJODJaZTUrRDMwNXpSSVE3VDEvVG5pUTNSbzFlTEtTUUw2ZENPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[17]</b>
                                        Sung YK, Chung L.Connective tissue disease-associated pulmonary arterial hypertension[J].Rheum Dis Clin North Am, 2015, 41 (2) :295-313.
                                    </a>
                                </li>
                                <li id="38">


                                    <a id="bibliography_18" title="Bourge RC, Waxman AB, Gomberg-Maitland M, et al.Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System:Results:of the Dell Very for PAH Trial[J].Chest, 2016, 150 (1) :27-34." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES2699D33D5EAC2C3A2531094E238456C1&amp;v=MDc0NDF0Qmh4TDI4d2FrPU5pZk9mYkcrRjlpNHJJd3hZWjUrZjM1S3pHY1I3eng4U0hibTJSQTJjYmFSUThtZUNPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[18]</b>
                                        Bourge RC, Waxman AB, Gomberg-Maitland M, et al.Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System:Results:of the Dell Very for PAH Trial[J].Chest, 2016, 150 (1) :27-34.
                                    </a>
                                </li>
                                <li id="40">


                                    <a id="bibliography_19" title="Mathai SC, Danoff SK.Management of interstitial lung disease associated with connective tissue disease[J].BMJ, 2016, 352:h6819." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Management of interstitial lung disease associated with connective tissue disease">
                                        <b>[19]</b>
                                        Mathai SC, Danoff SK.Management of interstitial lung disease associated with connective tissue disease[J].BMJ, 2016, 352:h6819.
                                    </a>
                                </li>
                                <li id="42">


                                    <a id="bibliography_20" title="Thakkar V.Connective tissue disease-related pulmonary arterial hypertension[J].Best Pract Res Clin Rheumatol, 2016, 30 (1) :22-38." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Connective tip SSue disease-related pulmonary arterial hypertension">
                                        <b>[20]</b>
                                        Thakkar V.Connective tissue disease-related pulmonary arterial hypertension[J].Best Pract Res Clin Rheumatol, 2016, 30 (1) :22-38.
                                    </a>
                                </li>
                                <li id="44">


                                    <a id="bibliography_21" title="Enderle Y, Witt L, Wilkens H, et al.Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension[J].J Pharm Biomed Anal, 2017, 143:291-298." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES11F82D2FF296031DE4E81C1970688DD7&amp;v=MDk1MTJwUlUxZjdxY01jNllDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4TDI4d2FrPU5pZk9mYks1YU5uTzI0MHpFdWtHQ253NnptSm03a3AxU1F6ag==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[21]</b>
                                        Enderle Y, Witt L, Wilkens H, et al.Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension[J].J Pharm Biomed Anal, 2017, 143:291-298.
                                    </a>
                                </li>
                                <li id="46">


                                    <a id="bibliography_22" title="Humbert M, Coghlan JG, Ghofrani HA, et al.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease:Results:from PATENT-1 and PATENT-2[J].Ann Rheum Dis, 2017, 76 (2) :422-426." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJRS&amp;filename=SJRS9A0F411C1611CE48E4F37B29A51519D8&amp;v=MzAxNDVGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhMMjh3YWs9TmlmWmZickpIcWZJcm80MlplME9EUTlNeXg1bTdrbCtUdzNncFdNd2VMZVZUTTZYQ09OdkZTaVdXcjdKSQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[22]</b>
                                        Humbert M, Coghlan JG, Ghofrani HA, et al.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease:Results:from PATENT-1 and PATENT-2[J].Ann Rheum Dis, 2017, 76 (2) :422-426.
                                    </a>
                                </li>
                                <li id="48">


                                    <a id="bibliography_23" title="Noel ZR, Kido K, Macaulay TE.Selexipag for the treatment of pulmonary arterial hypertension[J].Am J Heacth Syst Pharm, 2017, 74 (15) :1135-1141." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK6D1922BA4DE37681295A4D90F10D9DF6&amp;v=MTgwNjA0em9NVEF2cnJHUTBlY2FkTWN5WkNPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhMMjh3YWs9TmlmY1piWE1IOWpPcmYwMFlKOTZEM3MveHhjUg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[23]</b>
                                        Noel ZR, Kido K, Macaulay TE.Selexipag for the treatment of pulmonary arterial hypertension[J].Am J Heacth Syst Pharm, 2017, 74 (15) :1135-1141.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=XXGK" target="_blank">心血管康复医学杂志</a>
                2019,28(03),369-372 DOI:10.3969/j.issn.1008-0074.2019.03.27            </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm"><b>结缔组织病相关肺动脉高压的诊断与治疗现状</b></span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E6%99%AF%E9%A9%B0&amp;code=42079053&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">景驰</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E5%90%B4%E7%82%B3%E7%A5%A5&amp;code=22929578&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">吴炳祥</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E5%93%88%E5%B0%94%E6%BB%A8%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%BA%8C%E5%8C%BB%E9%99%A2%E5%BF%83%E8%A1%80%E7%AE%A1%E5%86%85%E7%A7%91&amp;code=1044277&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">哈尔滨医科大学附属第二医院心血管内科</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p>结缔组织病相关肺动脉高压是常见肺动脉高压之一, 其发病机制复杂, 预后较差。近年来, 随着对结缔组织病相关肺动脉高压的认识越来越深入和靶向药物的不断发展, 对结缔组织病相关肺动脉高压的诊断和治疗取得了新的进展, 早期诊断、早期治疗可显著控制病情、改善预后。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E9%AB%98%E8%A1%80%E5%8E%8B%2C%20%E8%82%BA%E6%80%A7&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">高血压, 肺性;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E7%BB%93%E7%BC%94%E7%BB%84%E7%BB%87%E7%96%BE%E7%97%85&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">结缔组织疾病;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E8%AF%8A%E6%96%AD&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">诊断;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                            <b>作者简介：</b>
                                                        <span>
                                    *吴炳祥, E-mail:wubingxiang1964@163.com;
                                </span>
                    </p>
                                    <p><b>收稿日期：</b>2018-01-09</p>

            </div>
                    <h1>Current condition of diagnosis and treatment of connective tissue disease-related pulmonary artery hypertension</h1>
                    <h2>
                    <span>JING Chi</span>
                    <span>WU Bing-xiang</span>
            </h2>
                    <h2>
                    <span>Department of Cardiology, Second Affiliated Hospital of Harbin Medical University</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p>Connective tissue disease (CID) -related pulmonary arterial hypertension (PAH) is one of frequent PAH, whose pathogenesis is complicated and prognosis is poor. In recent years, with deepening understanding of CID-related PAH and development of targeted drugs, diagnosis and treatment of CID-related PAH achieve new progress, and early diagnosis and treatment can significantly control disease condition and improve prognosis.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Hypertension%2C%20pulmonary&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Hypertension, pulmonary;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Connective%20tissue%20diseases&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Connective tissue diseases;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Diagnosis&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Diagnosis;</a>
                </p>
            </div>
                    <div class="brief">
                
                    <p>
                            <b>Author：</b>
                                                        <span>
                                    WU Bing-xiang, E-mail: wubingxiang1964@163.com;
                                </span>
                    </p>
                                    <p><b>Received：</b> 2018-01-09</p>
                            </div>


        <!--brief start-->
                        <div class="p1">
                    <p id="50">肺动脉高压 (PAH) 是指肺动脉血压增高而肺静脉压力正常, 主要原因是肺小动脉原发病变而导致的肺动脉阻力增加, 表现为肺动脉压力升高而肺静脉压力在正常范围内。其主要特征是肺动脉阻力进行性升高, 最终导致患者因右心衰竭死亡<citation id="90" type="reference"><link href="3" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>。2013年法国尼斯肺高血压分类中, 仍将肺高血压分为五大类, 结缔组织病相关肺动脉高压 (CTD-PAH) 仍然是第一大类PAH的一个重要亚分类<citation id="91" type="reference"><link href="5" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。由于PAH本身没有特异性的临床表现, 尤其是合并结缔组织病 (CTD) 时, 更容易漏诊和误诊, 延误治疗时机, 导致病情加重, 预后不佳。PAH已经成为结缔组织病患者病情加重甚至死亡的重要原因之一<citation id="92" type="reference"><link href="7" rel="bibliography" /><sup>[<a class="sup">3</a>]</sup></citation>, 因此应对结缔组织病的患者及早进行PAH的筛查, 及早诊断, 及时干预, 改善预后。现就CTD-PAH的流行病学、发病机制、诊断及治疗等方面进行综述。</p>
                </div>
                <h3 id="51" name="51" class="anchor-tag"><b>1 流行病学</b></h3>
                <div class="p1">
                    <p id="52">根据近几年国外的注册登记研究结果, 肺动脉高压可以在任何年龄发生, 其平均诊断年龄为36岁, 中位生存时间为2.8年, 从症状出现到确诊的平均时间为2年, 有家族史的肺动脉高压患者时间更短。美国最新的肺高压 (PH) 注册研究显示, 在相关因素所致PAH亚组中, CTD所占比例高达49.9%, 不同的 CTD 其发病率也有较大差异。CTD-PAH 最常见于系统性硬化症 (SSc) 、混合性 CTD 及系统性红斑狼疮 (SLE) , 其患病率分别为 4.9%～ 38%、23% ～29% 和 2%～ 14%<citation id="93" type="reference"><link href="9" rel="bibliography" /><sup>[<a class="sup">4</a>]</sup></citation>, 但是在中国人群中导致 PAH 最常见的结缔组织病是 SLE。我国目前一项最大规模的多中心研究结果显示, 中国结缔组织病相关 PAH 患者中 49% 为 SLE, 而系统性硬化症相关 PAH 仅占 6%, PAH 是导致 CTD 患者死亡的重要原因之一, 系统性红斑狼疮确诊 PAH 后 2年总病死率高达 25%～50%<citation id="94" type="reference"><link href="11" rel="bibliography" /><sup>[<a class="sup">5</a>]</sup></citation>, 未经治疗的系统性硬化症伴发的 PAH 平均生存时间仅 1 年, 38% 的混合性 CTD 死亡原因与 PAH有关。一项包括 2000 例 CTD 患者的 20 年随访研究表明, 肺部疾病占全部死因的 21.5%, 其中 PAH占 53.3%, PAH 是 CTD 继感染和脏器衰竭后的第三位死亡原因。</p>
                </div>
                <h3 id="53" name="53" class="anchor-tag"><b>2 发病机制</b></h3>
                <div class="p1">
                    <p id="54">CTD 相关 PAH 的发病机制复杂, 目前尚不完全清楚。多数研究证实 PAH 往往是多因素共同作用的结果, 其中自身免疫反应及炎症是其发生和进展的主要因素。PAH的发病与肺动脉结构和功能的改变有关, 包括肺小动脉的收缩、肺血管壁增厚以及血栓形成等, 以上改变最终导致肺血管阻力增加、PAH 形成<citation id="95" type="reference"><link href="13" rel="bibliography" /><sup>[<a class="sup">6</a>]</sup></citation>。伴有雷诺现象的 CTD 患者临床 PAH 的发生率较高, 研究表明雷诺现象的发生与小动脉收缩有关, 当小动脉收缩发生于肺血管时有人将其称作“肺雷诺现象”。在缺氧或寒冷等情况下, 可以引起肺小动脉痉挛收缩, 肺循环阻力增加。长期的肺血管痉挛改变, 最终可导致肺血管结构性改变。肺血管结构性改变是 PAH 预后不良的根本原因, 该过程涉及多种细胞、离子和血管活性物质<citation id="96" type="reference"><link href="15" rel="bibliography" /><sup>[<a class="sup">7</a>]</sup></citation>。CTD-PAH 肺血管病理显示肺血管内膜弥漫性增厚和管腔狭窄, 并且有抗核抗体、类风湿因子、IgG 和补体的沉积, 同时可见巨噬细胞、T 淋巴细胞等炎性细胞侵润, 这也说明 CTD- PAH 的发生与免疫机制密切相关。</p>
                </div>
                <h3 id="55" name="55" class="anchor-tag"><b>3 临床表现</b></h3>
                <div class="p1">
                    <p id="56">CTD-PAH 的临床表现主要包括CTD 本身的表现和 PAH 的表现两个方面。CTD 最主要的特征是多系统受累, 例如皮肤黏膜、肌肉关节、浆膜、肾脏、神经系统、血液系统等<citation id="97" type="reference"><link href="17" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>。在 PAH 的临床特征方面, 早期主要表现为活动耐量下降、呼吸困难、咯血、晕厥等, 逐渐出现呼吸困难症状加重, 甚至右心功能不全、反复晕厥等。辅助检查方面, 随疾病进展可出现N末端脑钠肽前体 (NT-pro BNP) 升高, 肺功能检查显示用力肺活量下降, 一氧化碳弥散率下降, 超声心动图显示右心扩大, 右心功能不全表现等<citation id="98" type="reference"><link href="19" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>。与特发性 PAH 患者相比, CTD-PAH 患者往往年龄更大、女性更多、雷诺现象及心包积液发生率更高、心输出量更低、肺弥散功能更差、NT-pro BNP水平更高、预后更差。</p>
                </div>
                <h3 id="57" name="57" class="anchor-tag"><b>4 诊 断</b></h3>
                <div class="p1">
                    <p id="58">CTD-PAH 缺乏早期临床表现, 故 PAH 诊断多数为中晚期。因此对于诊断 CTD 的患者要做 PAH相关的筛查, 以便及早治疗, 延缓病情恶化。目前可辅助 PAH 诊断的检查包括:心电图、胸部 X 线片、肺功能和动脉血气分析、肺部 CT、超声心动图及右心导管检查<citation id="99" type="reference"><link href="21" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>。PAH 是一个血流动力学概念, 其诊断标准是:在海平面、静息状态下、右心导管测得的肺动脉平均压≥25 mmHg。右心导管检查是诊断 PAH 的“金标准”, 可以直接测定肺动脉平均压、肺毛细血管楔压、肺血管阻力和心排血量等。但此法为有创检查, 不为大多数患者接受。超声心动图检查与右心导管检查有一定的相关性。2010 年中国 PAH 专家共识建议超声心动图检查提示三尖瓣反流速度&gt;3.4 m/s, 估测肺动脉收缩压&gt;50 mmHg, 无论是否合并 PAH 的其他征象, 应高度怀疑 PAH。三尖瓣反流速度≤2.8 m/s, 估测肺动脉收缩压≤36 mmHg, 且合并其他提示的PAH 征象, 应考虑 PAH 可能; 若无其他 PAH 征象, 可排除 PAH<citation id="100" type="reference"><link href="23" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。但超声心动图估测的肺动脉收缩压往往比右心导管测得的压力值高10 mmHg以上, 部分患者可能被低估, 超声心动图可作为CTD-PAH患者的初步筛查工具, 但高度怀疑PAH患者必须通过右心导管检查来确诊。</p>
                </div>
                <h3 id="59" name="59" class="anchor-tag"><b>5 治 疗</b></h3>
                <div class="p1">
                    <p id="60">PAH 目前的治疗取得了迅速的进展, 患者的生存质量和预后显著改善, 但仍无法完全治愈。CTD相关 PAH 的治疗包括一般治疗、针对 CTD 的治疗、PAH 靶向药物治疗和其他治疗<citation id="101" type="reference"><link href="25" rel="bibliography" /><sup>[<a class="sup">12</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="61" name="61">5.1 一般治疗</h4>
                <div class="p1">
                    <p id="62">一般治疗包括适量运动、预防感染、避孕、绝经期雌激素替代治疗及心理治疗等。适量的运动有助于提高患者的运动耐量, 但应以不引起显著的气短、眩晕、晕厥为宜。感染是加重和导致PAH 患者死亡的重要原因, 因此, 一定要注意预防感染。PAH 患者妊娠期病死率高达 30% ～ 50%, 故育龄女性患者应注意采取有效的避孕措施<citation id="102" type="reference"><link href="27" rel="bibliography" /><sup>[<a class="sup">13</a>]</sup></citation>。PAH 患者加之原发病的困扰, 往往伴有焦虑和抑郁的心理疾病, 这也是导致 PAH 患者预后不良的重要因素。</p>
                </div>
                <h4 class="anchor-tag" id="63" name="63">5.1.1 氧疗:</h4>
                <div class="p1">
                    <p id="64">研究表明长期氧疗有助于阻止或延缓PAH 的发展, 并且可以改善运动耐量, 但长期氧疗是否有助于改善预后尚不明确。中国 PAH 治疗指南建议, 动脉血氧饱和度低于 90%建议常规吸氧治疗<citation id="103" type="reference"><link href="29" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="65" name="65">5.1.2 抗凝治疗:</h4>
                <div class="p1">
                    <p id="66">在特发性肺动脉高压患者中, 长期抗凝能延长生存期, 在CTD-PAH患者的肺组织中也可发现类似的微小血栓性病理改变<citation id="104" type="reference"><link href="32" rel="bibliography" /><sup>[<a class="sup">15</a>]</sup></citation>, 同时, 抗磷脂抗体阳性的患者, 容易并发血栓, 因此, 对于无禁忌症的患者, 推荐抗凝治疗, 常用药物有低分子肝素和华法林, 口服华法林的目标值为国际标准化比值 (INR) 维持在 2.0～ 2.5。</p>
                </div>
                <h4 class="anchor-tag" id="67" name="67">5.1.3 钙通道阻滞剂:</h4>
                <div class="p1">
                    <p id="68">CTD-PAH患者对钙通道阻滞剂的治疗反应远低于特发性肺动脉高压 (IPAH) , 只有急性肺血管扩张试验阳性的患者才能从钙通道阻滞剂治疗中获益。<citation id="105" type="reference"><link href="34" rel="bibliography" /><sup>[<a class="sup">16</a>]</sup></citation>由于钙通道阻滞剂有导致体循环血压下降, 矛盾性肺动脉压力升高, 心功能衰竭加重, 诱发肺水肿等危险, 故对未进行急性肺血管扩张试验的患者不能盲目应用钙通道阻滞剂。对正在服用且疗效不佳的患者应该逐渐减量至停用, 常用药物有硝苯地平、地尔硫卓等。</p>
                </div>
                <h4 class="anchor-tag" id="69" name="69">5.2 针对 CTD 的治疗</h4>
                <div class="p1">
                    <p id="70">CTD 相关肺动脉高压的治疗, 其中 CTD 的治疗是一个重要的环节, 尤其是 CTD病情活动时。CTD 的治疗主要是应用激素和 (或) 免疫抑制剂<citation id="106" type="reference"><link href="36" rel="bibliography" /><sup>[<a class="sup">17</a>]</sup></citation>。激素通常使用甲泼尼龙或醋酸泼尼松, 其用法和用量要根据病情进行选择。免疫抑制剂包括环磷酰胺、霉酚酸酯、环孢素等。研究表明, 应用激素和 (或) 免疫抑制剂治疗 CTD, 尤其是系统性红斑狼疮, 控制和保持病情稳定, 对于改善 CTD 相关肺动脉高压的病情和预后十分重要。</p>
                </div>
                <h4 class="anchor-tag" id="71" name="71">5.3 PAH 靶向药物治疗</h4>
                <h4 class="anchor-tag" id="72" name="72">5.3.1 前列腺素类制剂:</h4>
                <div class="p1">
                    <p id="73">前列腺素类制剂是治疗PAH的一线用药, 前列环素是花生四烯酸的代谢产物, 其通过活化环磷酸腺苷, 产生强有力的血管舒张和抗血小板聚集作用<citation id="107" type="reference"><link href="38" rel="bibliography" /><sup>[<a class="sup">18</a>]</sup></citation>。目前临床常用的药物主要有:依前列醇、 伊洛前列素、曲前列环素、贝前列素等药物。 (1) 依前列醇:第一个欧洲上市的前列腺素药物, 目前证实对各类PAH患者都有显著疗效, 包括CTD-PAH。SSc患者静脉输注依前列醇后, 活动耐力、心肺血流动力学、雷诺现象均有改善, 长期随访表明生存期亦延长, 依前列醇用于SLE相关的PAH也获得较好疗效; (2) 伊洛前列素:通常给药途径是雾化吸入, 起效快, 可快速改善血流动力学, 常作为危重患者的抢救用药, 效果显著。对重症PAH患者, 包括CTD-PAH的研究显示, 与安慰剂相比, 吸入性伊洛前列素对改善活动耐量、心功能分级、血流动力学都有显著疗效; (3) 曲前列环素:曲前列环素可以多种途径给药, 包括皮下注射、静脉注射及雾化吸入, 口服制剂的临床试验也正在进行中, 在CTD-PAH中, 静脉注射曲前列环素可以改善6min步行距离 (增加25m) , 显著降低肺血管阻力和呼吸困难指数; (4) 贝前列素:口服的贝前列素钠也显示出一定效果, 单药的长期疗效尚缺乏循证医学依据。</p>
                </div>
                <h4 class="anchor-tag" id="74" name="74">5.3.2 内皮素受体拮抗剂:</h4>
                <div class="p1">
                    <p id="75">内皮素是一种内源性血管收缩因子, 与血管壁的炎症、肥厚和纤维化有关。 (1) 波生坦:波生坦可以有效地减轻肺血管炎症、管壁增厚, 延缓PAH 的进展。波生坦被美国、加拿大及欧洲国家推荐用于PAH的治疗, 欧洲和美国指南认为该药是治疗心功能III级PAH患者的首选治疗药物<citation id="108" type="reference"><link href="40" rel="bibliography" /><sup>[<a class="sup">19</a>]</sup></citation>, 在欧洲, 该药推荐用于SSc继发中度PAH患者, 在我国注册的适应症有IPAH以及硬皮病相关PAH; (2) 安立生坦:安立生坦在欧洲及美国推荐用于PAH的治疗, 其肝功能损害发生率相对较低, 但对于CTD-PAH的疗效有待进一步观察, 在安立生坦治疗肺动脉高压疗效研究 (ARIES) -1和ARIES-2研究中, CTD-PAH患者在接受安立生坦治疗12周后6min步行距离可显著改善, 但24周后再次恢复到基线值, 在ARIES-3中, 共纳入224名患者, 其中CTD-PAH占18%, 所有患者服用安立生坦5mg, 1天1次, 24周, 治疗后所有患者平均6min步行距离增加21m, 但CTD-PAH亚组改善不显著<citation id="109" type="reference"><link href="42" rel="bibliography" /><sup>[<a class="sup">20</a>]</sup></citation>; (3) 马西替坦:马西替坦是从波生坦衍生而来的双向内皮素拮抗剂。与其它内皮素受体拮抗剂相比较, 关于成人的研究显示它可提高与受体结合能力, 增加活动耐量, 药物之间的相互作用少见, 无肝脏损伤, 降低死亡率与发病率, 马西替坦对肺动脉高压发病率和死亡率的作用 (SERAPHIN) 研究共纳入742例PAH患者, 随机分组接受安慰剂、马西替坦 3 mg、马西替坦10 mg, 前瞻性随访100周, 24周后马西替坦组6min步行距离较对照组都有所增加<citation id="110" type="reference"><link href="44" rel="bibliography" /><sup>[<a class="sup">21</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="76" name="76">5.3.3 磷酸二酯酶-5</h4>
                <div class="p1">
                    <p id="77">抑制剂:磷酸二酯酶-5抑制剂通过与环磷酸鸟苷特异性结合, 减少环磷酸鸟苷的降解, 环磷酸鸟苷是NO扩血管效应的第二信使, 抑制磷酸二酯酶-5可以显著增强NO的扩血管效应。 (1) 西地那非:西地那非被美国和欧洲推荐用于PAH的治疗, 可改善活动耐量并延缓病情进展。西地那非治疗PAH的随机、双盲安慰剂对照研究 (SUPER) -1研究对CTD-PAH亚组 (84/278) 分析, 经过12周的治疗后, 与安慰剂对比, 患者6min步行距离显著改善, WHO心功能分级改善及肺血管阻力下降; (2) 他达那非:他达那非被美国及欧洲证实可用于改善PAH的活动耐量。在他达那非治疗肺动脉高压 (PHIRST) 研究中, 共纳入PAH患者405例, 其中CTD-PAH患者89例, 研究证实, 无论是否合并使用波生坦, 使用他达那非均可以改善患者的活动耐量, 显著延缓疾病进展。</p>
                </div>
                <h4 class="anchor-tag" id="78" name="78">5.3.4 治疗新趋向:</h4>
                <div class="p1">
                    <p id="79">利奥西呱<citation id="111" type="reference"><link href="46" rel="bibliography" /><sup>[<a class="sup">22</a>]</sup></citation>是可溶性鸟苷酸环化酶 (sGC) 的激动剂。可溶性鸟苷酸环化酶是重要的信号传导酶, 可以被NO激活来催化三磷酸鸟苷 (GTP) 转化为第二信使环磷酸鸟苷 (cGMP) , 是目前唯一已知的NO受体。利奥西呱对PAH患者的安全性和有效性的Ⅲ期临床试验已经进行, 目前研究结果显示能够改善血流动力学和心功能分级。</p>
                </div>
                <div class="p1">
                    <p id="80">塞乐西帕 (Selexipag) <citation id="112" type="reference"><link href="48" rel="bibliography" /><sup>[<a class="sup">23</a>]</sup></citation>是一种高选择性的口服前列环素受体激动剂。一项临床试验纳入了1156例成人PAH患者, 接受Selexipag治疗1.4年 (中位数) , 结果显示该药有良好的安全性和有效性, 药物不良反应少, 与安慰剂相比可有效降低PAH住院率和疾病恶化风险<sup><a class="sup">[30]</a></sup>。Selexipag的不良反应包括头痛、腹泻、下颌疼痛、恶心、肌痛、呕吐、肢体疼痛及潮红等。</p>
                </div>
                <div class="p1">
                    <p id="81">酪氨酸激酶抑制剂病理学研究表明, PAH的发病与内皮细胞和平滑肌细胞的增殖显著相关, 同时 PAH 发病时一些生长因子 (如血管内皮生长因子等) 分泌显著增加。一些学者认为此种变化类似于肿瘤的发生, 因此, 一些研究者尝试应用抗肿瘤药物对 PAH 模型和患者进行试验性治疗, 如酪氨酸激酶抑制剂。</p>
                </div>
                <div class="p1">
                    <p id="82">Rho激酶抑制剂 Rho激酶通路激活是PAH患者发病机制中的一个重要环节, 使用Rho激酶抑制剂能够舒张肺血管, 降低肺动脉压力并逆转肺血管和右心室重构, 法舒地尔 (商品名:川威) 静脉注射可降低PAH的肺血管阻力和右室重构, 国内临床研究证实对PAH患者的急性血流动力学影响与吸入依洛前列素相似。</p>
                </div>
                <h4 class="anchor-tag" id="83" name="83">5.4 其他治疗</h4>
                <h4 class="anchor-tag" id="84" name="84">5.4.1 房间隔造瘘术:</h4>
                <div class="p1">
                    <p id="85">经以上治疗无显著缓解的患者, 可进行房间隔造瘘术, 通过降低右心室前负荷, 增加左心室充盈压和心排血量, 改善 PAH 患者的预后。</p>
                </div>
                <h4 class="anchor-tag" id="86" name="86">5.4.2 肺移植:</h4>
                <div class="p1">
                    <p id="87">经内科治疗无效的终末期 PAH 患者, 可进行肺移植。在国外, 单肺移植、双肺移植和心肺联合移植均可用于治疗终末期PAH。</p>
                </div>
                <h3 id="88" name="88" class="anchor-tag"><b>6 小 结</b></h3>
                <div class="p1">
                    <p id="89">CTD (如系统性硬化症、系统性红斑狼疮等) 是引起肺动脉高压的常见疾病之一, 而 CTD-PAH的早期症状相当隐匿且缺乏特异性, 给早期诊断和治疗带来困难。采用超声心动图结合右心导管检测方法对 CTD-PAH的高危患者进行早期筛查和诊断, 以便早期发现, 早期药物干预, 以延缓病情进展, 延长生存期。前列环素类制剂、磷酸二酯酶-5抑制剂、内皮素受体拮抗剂是被证实对控制PAH有效的三类药物, 但对CTD-PAH亚组研究的数据还非常少, 同时, CTD-PAH是一个跨学科疾病, 为了更好地早期诊断和早期治疗, 相关学科需要更密切的合作。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="3">
                            <a id="bibliography_1" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK88E6CF190AE56E397A298D9FCFB25E9E&amp;v=MjE3MTh1d2E5ZS8yWTVNWkpwNkNYcE16QjhVbXoxMFFBdnIybUZEQzdDUk1MUHFDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4TDI4d2FrPU5pZmNaYg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[1]</b>Cavagna L, Codullo V, Ghio S, et al.Undiagnosed connective tissue diseases:High prevalence in pulmonary arterial hypertension patients[J].Medicinel (Baltimore) , 2016, 95 (39) :e4827.
                            </a>
                        </p>
                        <p id="5">
                            <a id="bibliography_2" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14010600322695&amp;v=MDM3NTNZOUZaK2tOQ25VOG9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGc1hheE09TmlmT2ZiSzhIdERNcQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[2]</b>Simonneau G, Gatzoulis MA, Adatia I, et al.Updated clinical classification of pulmonary hypertension[J].J Am Coll of Cardiol, 2013, 62 (25 Suppl) :D34-41.
                            </a>
                        </p>
                        <p id="7">
                            <a id="bibliography_3" >
                                    <b>[3]</b>
                                Humbert M, Coghlan JG, Ghofrani HA, et al.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease:Results:from PATENT-1 and PATENT-2[J].Ann Rheum Dis, 2017, 76 (2) :422-426.
                            </a>
                        </p>
                        <p id="9">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJGT&amp;filename=SJGT13101400003310&amp;v=MTYxMzk1b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZzWGF4TT1OaWZNZXJLN0g5SE5xNDlGWk9zTUQzMA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b>Lynch JP, Belperio JA, Saggar R, et al.Pulmonary hypertension complicating connective tissue disease[J].Semin Respir Crit Care Med, 2013, 34 (5) :581-599.
                            </a>
                        </p>
                        <p id="11">
                            <a id="bibliography_5" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SYNK201510001&amp;v=MTI0MjNGWmJHNEg5VE5yNDlGWllRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqZ1VMN0pOalQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[5]</b>张卓莉.系统性红斑狼疮相关肺动脉高压[J].中国实用内科杂志, 2015, 35 (10) :807-809, 813.
                            </a>
                        </p>
                        <p id="13">
                            <a id="bibliography_6" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Definitions and diagnosis of pulmonary hypertension">

                                <b>[6]</b>Hoeper MM, Bogaard HJ, Condliffe R, et al.Definitions and diagnosis of pulmonary hypertension[J].J Am Coll Cardiol, 2013, 62 (25 Suppl) :D42-D50.
                            </a>
                        </p>
                        <p id="15">
                            <a id="bibliography_7" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Management of borderline pulmonary arterial hypertension associated with connective tissue diseases">

                                <b>[7]</b>Yoshifuji H.Management of borderline pulmonary arterial hypertension associated with connective tissue diseases[J].Nihon Rinsho Meneki Gakkai kaishi, 2014, 37 (6) :454-461.
                            </a>
                        </p>
                        <p id="17">
                            <a id="bibliography_8" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients">

                                <b>[8]</b>Hao YJ, Jiang X, Zhou W, et al.Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J].Eur Respir J, 2014, 44 (4) :963-972.
                            </a>
                        </p>
                        <p id="19">
                            <a id="bibliography_9" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJHD&amp;filename=SJHD14051200000329&amp;v=MTYyNzlUNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRnNYYXhNPU5pZkRhcks4SHRUTnJZOUZaT3NQRDM0d29CTQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[9]</b>Li J, Leng X, Li Z, et al.Chinese SLE treatment and research group registry:III.association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus[J].J Immunology Res, 2014, 2014:809389.
                            </a>
                        </p>
                        <p id="21">
                            <a id="bibliography_10" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK14061700000035&amp;v=MjU5OTZESDg4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZzWGF4TT1OaWZjWmJLOEh0Zk5xSTlGWk9zUA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[10]</b>Boueiz A.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension:Pulmonary arterial hypertension associated with connective tissue diseases[J].Ann Thoracic Med, 2014, 9 (Suppl 1) :S26-S37.
                            </a>
                        </p>
                        <p id="23">
                            <a id="bibliography_11" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=YXQY201102028&amp;v=MTY2ODc0SDlETXJZOUhiSVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpnVUw3SlBEWGFkN0c=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[11]</b>荆志成.2010 年中国肺高血压诊治指南[J/OL].中国医学前沿杂志:电子版, 2011, 3 (2) :62-81.
                            </a>
                        </p>
                        <p id="25">
                            <a id="bibliography_12" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES15122600406507&amp;v=MTI1MjlPc0pDWHcrb0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZzWGF4TT1OaWZPZmJLOUg5UE9xWTlGWQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[12]</b>Ruano CA, Lucas RN, Leal CI, et al.Thoracic manifestations of connective tissue diseases[J].Curr Probl Diagn Radiol, 2015, 44 (1) :47-59.
                            </a>
                        </p>
                        <p id="27">
                            <a id="bibliography_13" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus?A successful case of SLE-PAH cured by methylprednisolone pulse therapy">

                                <b>[13]</b>Huang C, Zhang S, Tian Z, et al.Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus?A successful case of SLE-PAH cured by methylprednisolone pulse therapy[J].Lupus, 2014, 23 (14) :1533-1536.
                            </a>
                        </p>
                        <p id="29">
                            <a id="bibliography_14" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Pulmonary hypertension in diffuse parenchymal lung diseases-is there any benefit of PAH-specific therapy">

                                <b>[14]</b>Szturmowicz M, Kacprzak A, Ku<mathml id="31"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mover><mstyle mathsize="140%" displaystyle="true"><mtext>s</mtext></mstyle><mo>'</mo></mover><mspace width="0.25em" /><mtext>J</mtext></mrow></math></mathml>.Pulmonary hypertension in diffuse parenchymal lung diseases-is there any benefit of PAH-specific therapy?[J].Adv Respir Med, 2017, 85 (4) :216-223.
                            </a>
                        </p>
                        <p id="32">
                            <a id="bibliography_15" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Connective tissue disease associated with pulmonary arterial hypertension:management of a patient with severe haemodynamic impairment">

                                <b>[15]</b>Sitbon O, Bertoletti L.Connective tissue disease associated with pulmonary arterial hypertension:management of a patient with severe haemodynamic impairment[J].Eur Respir Rev, 2014, 23 (134) :505-509.
                            </a>
                        </p>
                        <p id="34">
                            <a id="bibliography_16" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Connective tissue disease-associated pulmonary arterial hypertension">

                                <b>[16]</b>Condliffe R, Howard LS.Connective tissue disease-associated pulmonary arterial hypertension[J].F1000Prime Rep, 2015, 7:6.
                            </a>
                        </p>
                        <p id="36">
                            <a id="bibliography_17" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJESC5BEEC0C15A31024372267BA80106542&amp;v=MjI1NDlLUzUzSTgyWmU1K0QzMDV6UklRN1QxL1RuaVEzUm8xZUxLU1FMNmRDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4TDI4d2FrPU5pZk9mY0M5Yg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[17]</b>Sung YK, Chung L.Connective tissue disease-associated pulmonary arterial hypertension[J].Rheum Dis Clin North Am, 2015, 41 (2) :295-313.
                            </a>
                        </p>
                        <p id="38">
                            <a id="bibliography_18" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES2699D33D5EAC2C3A2531094E238456C1&amp;v=MTc0MzdPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhMMjh3YWs9TmlmT2ZiRytGOWk0ckl3eFlaNStmMzVLekdjUjd6eDhTSGJtMlJBMmNiYVJROG1lQw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[18]</b>Bourge RC, Waxman AB, Gomberg-Maitland M, et al.Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System:Results:of the Dell Very for PAH Trial[J].Chest, 2016, 150 (1) :27-34.
                            </a>
                        </p>
                        <p id="40">
                            <a id="bibliography_19" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Management of interstitial lung disease associated with connective tissue disease">

                                <b>[19]</b>Mathai SC, Danoff SK.Management of interstitial lung disease associated with connective tissue disease[J].BMJ, 2016, 352:h6819.
                            </a>
                        </p>
                        <p id="42">
                            <a id="bibliography_20" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Connective tip SSue disease-related pulmonary arterial hypertension">

                                <b>[20]</b>Thakkar V.Connective tissue disease-related pulmonary arterial hypertension[J].Best Pract Res Clin Rheumatol, 2016, 30 (1) :22-38.
                            </a>
                        </p>
                        <p id="44">
                            <a id="bibliography_21" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES11F82D2FF296031DE4E81C1970688DD7&amp;v=MTk4NjYyOHdhaz1OaWZPZmJLNWFObk8yNDB6RXVrR0NudzZ6bUptN2twMVNRempwUlUxZjdxY01jNllDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4TA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[21]</b>Enderle Y, Witt L, Wilkens H, et al.Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension[J].J Pharm Biomed Anal, 2017, 143:291-298.
                            </a>
                        </p>
                        <p id="46">
                            <a id="bibliography_22" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJRS&amp;filename=SJRS9A0F411C1611CE48E4F37B29A51519D8&amp;v=MTI5NDlmT0dRbGZCckxVMDV0Qmh4TDI4d2FrPU5pZlpmYnJKSHFmSXJvNDJaZTBPRFE5TXl4NW03a2wrVHczZ3BXTXdlTGVWVE02WENPTnZGU2lXV3I3SklGcG1hQnVIWQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[22]</b>Humbert M, Coghlan JG, Ghofrani HA, et al.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease:Results:from PATENT-1 and PATENT-2[J].Ann Rheum Dis, 2017, 76 (2) :422-426.
                            </a>
                        </p>
                        <p id="48">
                            <a id="bibliography_23" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK6D1922BA4DE37681295A4D90F10D9DF6&amp;v=MDAxOTM5ak9yZjAwWUo5NkQzcy94eGNSNHpvTVRBdnJyR1EwZWNhZE1jeVpDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4TDI4d2FrPU5pZmNaYlhNSA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[23]</b>Noel ZR, Kido K, Macaulay TE.Selexipag for the treatment of pulmonary arterial hypertension[J].Am J Heacth Syst Pharm, 2017, 74 (15) :1135-1141.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="XXGK201903028" />
        <input id="dpi" type="hidden" value="200" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>

    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201903028&amp;v=MjU3MjFyQ1VSN3FmWnVabUZ5amdVTDdKUFRYTVpiRzRIOWpNckk5SGJJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0Y=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>

</body>
</html>
